MEK1/2 inhibitors in the treatment of gynecologic malignancies.
about
The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapyMedical treatment of early stage and rare histological variants of epithelial ovarian cancerCentral role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic interventionMAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomasGenome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.Targeted inhibition of MEK1 by cobimetinib leads to differentiation and apoptosis in neuroblastoma cells.Liposome-mediated RNA interference delivery against Erk1 and Erk2 does not equally promote chemosensitivity in human hepatocellular carcinoma cell line HepG2.MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro.MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.PIMASERTIB AND SEROUS RETINAL DETACHMENTSEnhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.Cisplatin promotes mesenchymal-like characteristics in osteosarcoma through Snail.The MEK-Inhibitor Selumetinib Attenuates Tumor Growth and Reduces IL-6 Expression but Does Not Protect against Muscle Wasting in Lewis Lung Cancer Cachexia.A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities.Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor γ-independent mechanism.Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.The thyroid hormone-αvβ3 integrin axis in ovarian cancer: regulation of gene transcription and MAPK-dependent proliferation.The future role of molecular staging in gynecologic cancer.Endometrial Carcinoma: Specific Targeted Pathways.Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients.Silencing of type Iγ phosphatidylinositol phosphate kinase suppresses ovarian cancer cell proliferation, migration and invasion.Low-grade serous carcinoma of the ovary or peritoneum.Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition.Targeted therapy in gynecologic cancers: Ready for prime time?ERK1/2 promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins.Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment.Towards precision informatics of pharmacovigilance: OAE-CTCAE mapping and OAE-based representation and analysis of adverse events in patients treated with cancer drugs.A natural ent‑kaurane diterpenoid induces antiproliferation in ovarian cancer cells via ERK1/2 regulation and inhibition of cellular migration and invasion
P2860
Q26744087-B60429DB-837F-47D4-A0E8-841327B31A2BQ26777702-39816792-744A-40FB-9E9B-C91B1935E99FQ26864839-5F8C10A1-54EF-4A06-A4F4-1A435E258DDFQ28393224-E3F968FE-C494-474C-B206-3096C06B95BDQ33598001-3C24A5A2-C5E5-4CC4-947D-51B3EBFFE5A5Q36073804-71BB6C63-44C0-4033-864E-23DB87930392Q36241772-8530CEAC-2885-4621-B2B0-4D5C38EB6DEBQ36328021-39634DD3-6213-44D2-BF34-3AEA299EDBCFQ36396095-52D67F42-32D0-4BC4-9009-3B551EA84499Q36586093-E06C893E-54FD-4ABF-8FC6-950351733209Q36961790-7001C0DD-60F5-4CDD-923C-2F0CAA29A92CQ37421296-5D5F82B0-CC75-4275-A38C-2CE46F547BFFQ37582414-326EEDA3-CA6E-45CC-BAA3-F6D6C4B0AD47Q37590551-F10B3C63-1BD2-4BC8-8735-6E51D2C1C720Q37639582-B1F5DFB0-D1CF-4822-9C0F-456A983CEC0BQ38444096-E5CE7DC7-963C-4F4B-991F-637DAC5D08ABQ38733117-4423E3AC-5A0E-4158-AEA9-EC049288AC16Q38744037-EFA1C37A-C2DD-40DC-BCF6-7A5074552A81Q38813996-FB2D59BC-2D93-4247-B1C6-52F65B67D31CQ38854040-F2793ED9-6F76-480E-8469-DDBC59DA6FCCQ38957038-58456D9E-E81C-4CF5-8904-0DD06FACA553Q39026766-A8111042-CA29-4017-B01B-962606A52CAEQ47685928-997285B4-8AB3-4F94-9860-233DE0C2724DQ50611919-C0B63660-7179-4870-B1D4-EF714D1CF232Q50856533-67EECAC9-2BE2-4C78-B6A3-3E59FDC4583CQ51006519-2FB9DF34-CD39-4DC4-9663-BDE8F4A47620Q53322899-E0C3BF71-C724-4FA0-B064-202ECC679C5CQ53627379-F1D79B02-D01A-48A6-BAB5-B15F15873AB7Q55354383-BD4FA86C-39EC-40A0-9F9A-CE16D348DF99Q55361610-61F110BF-597F-446C-9059-7596111916B3Q58792243-B0D511BB-7CE2-45D1-99F9-E88EA10CDA2C
P2860
MEK1/2 inhibitors in the treatment of gynecologic malignancies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
MEK1/2 inhibitors in the treatment of gynecologic malignancies.
@en
type
label
MEK1/2 inhibitors in the treatment of gynecologic malignancies.
@en
prefLabel
MEK1/2 inhibitors in the treatment of gynecologic malignancies.
@en
P1433
P1476
MEK1/2 inhibitors in the treatment of gynecologic malignancies
@en
P2093
Caela R Miller
John H Farley
P304
P356
10.1016/J.YGYNO.2014.01.008
P407
P577
2014-01-14T00:00:00Z